Spero Therapeutics, Inc. cash flow to debt ratio of -436.06% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Spero Therapeutics, Inc.'s free cash flow has increased -46.15% from $-23.44M last year to $-12.62M, signaling increasing performance

Spero Therapeutics, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Spero Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.05 today, signaling strengthened financials

Spero Therapeutics, Inc. has a net cash position, so leverage is healthy.

Spero Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Spero Therapeutics, Inc.'s profit margin has increased (-119.47%) in the last year from -142.91% to 27.82%, signaling increasing performance

Spero Therapeutics, Inc.'s short-term assets of $67.29M exceed its short-term liabilities of $8.87M

Spero Therapeutics, Inc.'s return on assets of 25.81% is higher than the 5.00% threshold, indicating efficient asset utilization

Spero Therapeutics, Inc.'s return on equity of 35.58%, is higher than 15.00%, indicating good performance

Spero Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Spero Therapeutics, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Spero Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Spero Therapeutics, Inc. has negative free cash flow, indicating cash burn

Spero Therapeutics, Inc.'s yearly earnings has increased -112.50% since last year from $-68.57M to $8.57M, signaling increasing performance

Spero Therapeutics, Inc.'s yearly revenue has increased 143.84% since last year from $27.40M to $66.80M, signaling increasing performance

ROIC 23.93% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Spero Therapeutics, Inc.'s 3-year revenue CAGR of 7.06% is positive, indicating growing revenue over the past 3 years

Spero Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Spero Therapeutics, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Spero Therapeutics, Inc. has insufficient data to evaluate this check.

Spero Therapeutics, Inc. has an earnings yield of 21.63%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Spero Therapeutics, Inc. is overvalued relative to its fair value price of 0.65 based on EBITDA multiple model

Spero Therapeutics, Inc. has an EV/EBITDA ratio of 3.83x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Spero Therapeutics, Inc. is overvalued relative to its fair value price of -16.98 based on Earnings Fair Value model

Spero Therapeutics, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Spero Therapeutics, Inc. has a price-to-book ratio of 1.33x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Spero Therapeutics, Inc. has a price-to-sales ratio of 1.29x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue